CERo Therapeutics (CERO) Stock Price, News & Analysis

Company Overview

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.

Key Stats

• Today's Range: $0.68 to $0.74
• 50-Day Range: $0.59 to $1.67
• 52-Week Range: $0.53 to $138.00
• Volume: 522,730 shs
• Average Volume: 760,527 shs
• Market Capitalization: $3.77 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.00
• Consensus Rating: Strong Buy

CERo Therapeutics Stock Analysis - MarketRank™

CERo Therapeutics scored higher than 71% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Strong Buy

Consensus Rating

CERo Therapeutics has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

CERo Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: N/A
• Proj. Earnings Growth: N/A

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

8.12% of the float of CERo Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

CERo Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CERo Therapeutics has recently decreased by 9.61%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CERo Therapeutics does not currently pay a dividend.

Dividend Growth

CERo Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

8.12% of the float of CERo Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

CERo Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CERo Therapeutics has recently decreased by 9.61%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: N/A

News Sentiment

CERo Therapeutics has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for CERo Therapeutics this week, compared to 1 article on an average week.

Search Interest

2 people have searched for CERO on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

5 people have added CERo Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CERo Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

18.00% of the stock of CERo Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 29.64% of the stock of CERo Therapeutics is held by institutions.

CERO Stock Analysis - Frequently Asked Questions

How have CERO shares performed this year?

CERo Therapeutics' stock was trading at $6.00 at the start of the year. Since then, CERO shares have decreased by 88.4% and is now trading at $0.6940.
View the best growth stocks for 2025 here.

When did CERo Therapeutics' stock split?

CERo Therapeutics shares reverse split on the morning of Wednesday, January 8th 2025. The 1-100 reverse split was announced on Monday, January 6th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 7th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Who are CERo Therapeutics' major shareholders?

CERo Therapeutics' top institutional shareholders include Parallel Advisors LLC (7.26%) and Avantax Planning Partners Inc. (2.45%). Insiders that own company stock include Stuart M Sloan and Bioventures Opportunities G Yk.
View institutional ownership trends.

How do I buy shares of CERo Therapeutics?

Shares of CERO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of CERo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that CERo Therapeutics investors own include Verve Therapeutics (VERV), Lithium Americas (LAC), NVIDIA (NVDA), Maxeon Solar Technologies (MAXN), ARM (ARM), AST SpaceMobile (ASTS) and BigBear.ai (BBAI).

Company Calendar

• Today: 5/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CERO
• Previous Symbol: NASDAQ:CERO
• CIK: 1870404
• Web: www.cero.bio
• Phone: 215-731-9450
• Fax: N/A
• Employees: 8
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $11.00
• High Stock Price Target: $11.00
• Low Stock Price Target: $11.00
• Potential Upside/Downside: +1,485.0%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-2,540,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -108.43%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.39
• Quick Ratio: 0.39

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($259.05) per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 5,381,000
• Free Float: 2,485,000
• Market Cap: $3.73 million
• Optionable: N/A
• Beta: 0.66